TXG logo

TXG
10x Genomics Inc - Ordinary Shares - Class A

2,784
Mkt Cap
$3.13B
Volume
3.8M
52W High
$26.45
52W Low
$8.31
PE Ratio
-135.78
TXG Fundamentals
Price
$23.68
Prev Close
$24.68
Open
$24.50
50D MA
$21.70
Beta
1.98
Avg. Volume
2.51M
EPS (Annual)
-$0.3491
P/B
3.75
Rev/Employee
$545,690.15
$1,595.62
Loading...
Loading...
News
all
press releases
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
Key PointsQuantedge Capital added 212,600 shares of 10x Genomics in the first quarter; the estimated transaction value was $4.25 million based on quarterly average pricing...
News Placeholder
More News
News Placeholder
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
News Placeholder
10x Genomics (TXG) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
News Placeholder
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
News Placeholder
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +65.52% and +3.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
10x Genomics Reports First Quarter 2026 Financial Results
10x Genomics Reports First Quarter 2026 Financial Results 10x Genomics Reports First Quarter 2026 Financial Results PR Newswire PLEASANTON, Calif., May 7, 2026 PLEASANTON, Calif., May 7, 2026...
News Placeholder
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
News Placeholder
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
M&T Bank Corp Has $1.19 Million Stake in 10x Genomics $TXG
M&T Bank Corp boosted its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 258.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,188 shares of the company's stock after purchasing an additional 52,771 shares du...
News Placeholder
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available